Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus
about
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccinePre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetNew pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesVaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.Oral adenoviral-based vaccines: historical perspective and future opportunity.Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.The chimpanzee model for hepatitis B virus infection.Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.Adenovirus as vehicle for anticancer genetic immunotherapy.Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.Packaging capacity and stability of human adenovirus type 5 vectors.Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant.Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen.DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.Novel approaches to oral immunization for hepatitis B.Helper independent recombinant adenovirus vectors: expression of HIV env or HBV surface antigen.Prospects for oral replicating adenovirus-vectored vaccines.Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus.Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene.Firewalls Prevent Systemic Dissemination of Vectors Derived from Human Adenovirus Type 5 and Suppress Production of Transgene-Encoded Antigen in a Murine Model of Oral Vaccination.Noninvasive vaccination against infectious diseases.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q21134724-54207438-7ECF-4DC1-919F-E80E0FC22EDCQ28731982-72C0AA62-5F75-48ED-B1E7-40CE31D600DAQ30226988-3527F099-E69B-40DD-90A4-303312E60347Q30227194-021A9852-2062-4313-9F89-B3B5A29E9020Q30365380-D4195F0E-A408-40E5-8A54-D0C4E13505A7Q30371162-C25FC717-B63D-46A3-B677-9F7F33F04FAFQ30382097-A866784A-CE46-4C39-A4B4-55575033AA8BQ30427591-62711FB2-070D-48C8-AE67-298818BDBDF2Q33786386-CC376E5C-205E-4007-AEF1-FED126D200E7Q34033882-25585E3A-F6EE-4559-BA7F-7B82C95EED3CQ34746476-48AEFF38-F050-4BC3-9321-5188E7D92E73Q34992681-FC7468E4-3BD5-470A-B4C4-DF410726C74BQ35664171-745E658B-AE97-4355-95B3-8CAB55BC7F1FQ35883639-B791BC6F-4F52-451B-8DF6-9D53F9E6BAB5Q36099144-411F6F86-CE96-48BC-9229-302249E143C9Q36209205-1F714F61-ECEE-45B6-BCA8-5E2A3BB37A60Q36288930-F53DC562-5139-4E14-93E8-E33AC36A92DFQ36427024-87BB996A-E664-4C09-AC03-3EDAE94C045EQ36504789-2441B859-8E8D-4D77-A8C0-0039334862CAQ36653293-511EEE9B-736B-47F4-ACDD-36EA5955CCA9Q36685348-2775066D-4F80-4A21-8EDA-5DD1E716F09AQ36699012-8658F681-2C7E-4320-9966-42CB36725655Q37164192-94FD2815-A283-45AD-81FE-B3B2B1DE586EQ37333844-284E3D6A-5A8E-48D0-8A72-6D7097DF49E3Q37495259-9B741FEE-9B49-4F5C-AEF6-4B930C675C49Q37838783-12134A28-A7C7-45EC-9A06-17726379A9D3Q37844073-3A3AAD19-0009-4E3E-A515-D90E2460AB7EQ38109356-D936FFD7-D32E-40F6-B5B8-D2E40DB5523AQ40012391-AD1C5353-DBD1-4567-850D-FB092F40C41DQ42981208-085761A8-A80D-4D8A-A061-C8A11C87A965Q45763265-2AEA6E7E-7A7F-4EDA-8602-5707821C6929Q49167770-054EAFB5-B64F-4730-BAE8-ABF1E229C6B7Q52602778-E3081CC7-8A5B-449F-A73A-945EF0F62204Q56993265-8AD9DD39-CDCE-41C3-8615-857AE14C735E
P2860
Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@ast
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@en
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@nl
type
label
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@ast
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@en
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@nl
prefLabel
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@ast
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@en
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@nl
P2093
P2860
P356
P1476
Immunogenicity and efficacy te ...... on live recombinant adenovirus
@en
P2093
Chengalvala M
Mizutani S
Molnar-Kimber K
P2860
P304
P356
10.1073/PNAS.86.17.6763
P407
P577
1989-09-01T00:00:00Z